Stockscreener 앱 받기
2.10
45.03%
-1.72
시간 외 거래:
2.11
0.010
+0.48%
전일 마감가:
$3.82
열려 있는:
$2.17
하루 거래량:
15.09M
Relative Volume:
18.71
시가총액:
$122.50M
수익:
-
순이익/손실:
$-73.79M
주가수익비율:
-0.7394
EPS:
-2.84
순현금흐름:
$-77.44M
1주 성능:
-50.93%
1개월 성능:
-42.93%
6개월 성능:
-47.50%
1년 성능:
+46.85%
1일 변동 폭
$1.90
$2.39
1주일 범위
$1.90
$4.40
52주 변동 폭
$1.35
$6.85
Pyxis Oncology Inc Stock (PYXS) Company Profile
명칭
Pyxis Oncology Inc
전화
(617) 221-9059
주소
321 HARRISON AVENUE, BOSTON
PYXS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| PYXS | 2.10 | 122.50M | 0 | -73.79M | -77.44M | -2.84 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-11-02 | 개시 | BofA Securities | Neutral |
| 2021-11-02 | 개시 | Credit Suisse | Outperform |
| 2021-11-02 | 개시 | Jefferies | Buy |
Pyxis Oncology Inc 주식(PYXS)의 최신 뉴스
Stock market news: Perspective Therapeutics -44.33%, Pyxis Oncology -42.93% among top losers during mid day trading - Business Upturn
Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade - MSN
Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade (NASDAQ:PYXS) - Seeking Alpha
Stock market today: Pyxis Oncology plunges by 47.25% while Perspective Therapeutics declines by 46.68% in early trading - Business Upturn
Stock market today: SCWorx Corp. gains 141.81% while Pyxis Oncology down by 46.41% in early trading - Business Upturn
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns - Benzinga
Pyxis Oncology (NASDAQ:PYXS) Downgraded to "Market Perform" Rating by William Blair - MarketBeat
HC Wainwright Reaffirms Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
Institutional investors in Pyxis Oncology, Inc. (NASDAQ:PYXS) lost 11% last week but have reaped the benefits of longer-term growth - Simply Wall St
Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - Seeking Alpha
Pyxis Oncology Reports Promising Phase 1 Trial Results - TipRanks
Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck - TipRanks
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - The Manila Times
Pyxis Oncology, Inc. Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data - Marketscreener.com
EPOCH 47: BIOTECH MARKET RESEARCH $PYXS - substack.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.57 Consensus Target Price from Analysts - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Up 19.3% in October - MarketBeat
Pyxis Oncology FY2024 EPS Forecast Lowered by HC Wainwright - MarketBeat
FY2024 EPS Estimates for Pyxis Oncology Reduced by Analyst - MarketBeat
Laurion Capital Management LP Adjusts Stake in Pyxis Oncology Inc - GuruFocus.com
Pyxis Oncology Inc (PYXS) Quarterly 10-Q Report - Quartzy
Pyxis Oncology to Host In-Person and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 - Marketscreener.com
Pyxis Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pyxis Oncology reports Q3 EPS (35c), consensus (31c) - TipRanks
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024 - The Manila Times
Pyxis Oncology Reports Strong Cash Position, Clinical Progress in Q3 Update | PYXS Stock News - StockTitan
Pyxis Oncology to host investor event to present preliminary PYX-201 data - TipRanks
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor - GlobeNewswire
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201 - Marketscreener.com
Pyxis Oncology to Reveal Key Phase 1 Trial Data for Novel Cancer Drug PYX-201 | PYXS Stock News - StockTitan
Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside - AOL
Pyxis Oncology (NASDAQ:PYXS) Now Covered by Analysts at Stephens - MarketBeat
Stephens & Co. Initiates Coverage of Pyxis Oncology (PYXS) with Overweight Recommendation - MSN
Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Bought by abrdn plc - MarketBeat
Pyxis Oncology Inc (PYXS) Stock Price & Chart | Trade Now - Capital.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Buy” from Analysts - Defense World
Pyxis Oncology expands equity plan by 5.5 million shares - Investing.com India
Pyxis Oncology Q3 EPS Estimate Reduced by Leerink Partnrs - MarketBeat
Financial Metrics Exploration: Understanding Pyxis Oncology Inc (PYXS) Through Ratios - The Dwinnex
Examining Pyxis Oncology Inc (PYXS) stock is warranted - US Post News
Millennium Management LLC Buys 743,499 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat
Upward Trajectory: Pyxis Oncology Inc (PYXS) Posts a Slidee, Closing at 3.51 - The Dwinnex
Pyxis Oncology's SWOT analysis: ADC developer's stock faces pivotal readout - Investing.com
Rhumbline Advisers Takes Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Blue Owl Capital Holdings LP Purchases New Holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) - MarketBeat
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS) - PR Newswire
ShiftPixy stock plunges to 52-week low at $0.9 amid market challenges - Investing.com
Prepare Yourself for Liftoff: Pyxis Oncology Inc (PYXS) - SETE News
Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Bought by Bank of New York Mellon Corp - MarketBeat
Pyxis Oncology Inc (PYXS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):